Regulatory strategy shaped by science and FDA review experience.

We support medical technology and pharmaceutical companies across U.S. FDA pathway strategy, evidence planning, submission preparation, and review response, from first concept through post-market compliance.

Deficiency response, biocompatibility strategy, chemical characterization, E&L, and pharmaceutical CMC (Chemistry, Manufacturing, and Controls): we've got you covered.

The difference isn't access to more information. Everything FDA expects is publicly available in guidance documents and the Code of Federal Regulations. The difference is knowing how a reviewer actually reads a submission: which claims draw scrutiny first, which testing gaps get flagged before anything else, and which arguments have already failed for other companies making a similar case.

That perspective shapes every engagement. We don't recommend testing because it's conventional or because a checklist calls for it. We recommend it because a specific risk in your device's profile requires it, and we can explain exactly why FDA will expect to see it addressed, not just that it should be.

Who We Work With

Indian MedTech & Pharma Companies

Indian device manufacturers and pharmaceutical sponsors seeking U.S. FDA clearance or approval, including 510(k), De Novo, PMA, NDA, and ANDA, who need a regulatory partner with direct FDA experience.

International Companies

Global medical device companies, including U.S., European, and APAC manufacturers, seeking support with U.S. FDA submissions, testing strategy, and CRO coordination for India-based studies.

CROs & Testing Laboratories

Contract research organisations and testing labs in India seeking scientific protocol design, regulatory alignment review, and expert guidance on what FDA actually requires from their studies.

Startups & Deep-Tech Ventures

Early-stage medical technology companies, including those in deep-tech incubators and innovation programs, building their regulatory strategy from the ground up, often for the first time.

Principle 01

Define the right regulatory question before generating the evidence.

Principle 02

Match evidence to risk , not to convention or volume.

Principle 03

Anticipate the reviewer's lens at every stage of the program.

Principle 04

Present the case as a technical argument that withstands expert review.

Because FDA review is not just document review.

Tacticity helps companies define the right questions early, generate the right evidence, and present the case clearly.

A reviewer isn't working through a checklist. They're tracing whether your risk assessment, your testing plan, and your claims all agree with each other, and where they don't, that gap becomes the first question you're asked. A submission can be complete on paper and still generate a deficiency, because completeness and a sound argument are not the same thing.

That distinction is what this practice is built around. We don't just assemble the documents a submission requires. We build the reasoning that has to survive contact with an actual reviewer: where the argument is genuinely strong, where it's merely assumed to be, and where it needs rebuilding before FDA finds the gap first.

The strength of a submission is determined by how clearly the evidence answers the relevant risk questions, not by its volume.